These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 26158698)

  • 1. A demonstration project implementing extended-release naltrexone in Los Angeles County.
    Cousins SJ; Denering L; Crèvecoeur-MacPhail D; Viernes J; Sugita W; Barger J; Kim T; Weimann S; Rawson RA
    Subst Abus; 2016; 37(1):54-62. PubMed ID: 26158698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).
    Cousins SJ; Crèvecoeur-MacPhail D; Kim T; Rawson RA
    J Subst Abuse Treat; 2018 Feb; 85():78-83. PubMed ID: 28291571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
    Cousins SJ; Radfar SR; Crèvecoeur-MacPhail D; Ang A; Darfler K; Rawson RA
    J Subst Abuse Treat; 2016 Apr; 63():66-71. PubMed ID: 26823295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release naltrexone for opioid use disorder started during or following incarceration.
    Lincoln T; Johnson BD; McCarthy P; Alexander E
    J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
    Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
    Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
    Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release naltrexone for youth with opioid use disorder.
    Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
    J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
    Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
    Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
    Friedmann PD; Wilson D; Nunes EV; Hoskinson R; Lee JD; Gordon M; Murphy SM; Bonnie RJ; Chen DT; Boney TY; O'Brien CP
    J Subst Abuse Treat; 2018 Feb; 85():61-65. PubMed ID: 28236511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
    Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
    J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
    Williams AR; Barbieri V; Mishlen K; Levin FR; Nunes EV; Mariani JJ; Bisaga A
    Am J Addict; 2017 Jun; 26(4):319-325. PubMed ID: 28328148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular extended-release naltrexone: current evidence.
    Gastfriend DR
    Ann N Y Acad Sci; 2011 Jan; 1216():144-66. PubMed ID: 21272018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
    Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
    Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
    Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
    Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.